Abstract 155P
Background
Nuclear auto-antigenic sperm protein (NASP) is a histone chaperone and a facilitator of chromatin assembly. One of two NASP splice variants, tNASP, is specific to the testis, where it is sequestered by the blood-testis barrier and also present in cancer cells. Exposure of tNASP from the cancer cells to the immune system induces a robust humoral immune response. We hypothesized that the autoantibodies produced against tNASP may be used as a supplementary diagnostic marker for prostate, pancreatic, and ovarian cancer.
Methods
Sera from patients with pancreatic cancer (74), prostate cancer (63), and ovarian cancer (19) were tested for the presence of antibodies against tNASP using enzyme-linked immunosorbent assay (ELISA) with a recombinant tNASP fragment as bait. Correlation analysis was used to determine correlations between anti-tNASP antibody level and the age, ethnicity, TMN staging, and diagnostic marker levels (PSA in the prostate cancer and CA19-9 in pancreatic cancer).
Results
Level of anti-tNASP antibody in prostate cancer patients ranged from 426 to 3810 μg/mL and was significantly higher compared to healthy individuals (p<0.01). The cutoff for anti-tNASP antibody thus was established at 400 μg/mL. Combined analysis of anti-tNASP and PSA tests demonstrated that 18% of PC patients with PSA higher than 4 ng/mL had a low level of anti-tNASP antibody (false positive PSA, supported by negative biopsy); 11.4% of PC patients with PSA lower than 4 ng/mL had high levels of anti-tNASP antibodies (false negative PSA, proved histologically). Level of anti-tNASP antibody in pancreatic cancer patients ranged from 564 to 2751 μg/mL and was significantly higher compared to healthy individuals (p<0.01). Correlations between expression of tNASP antibody and levels of CA19-9 are not conclusive. There is a significant difference in tNASP antibody concentrations between serum from patients with ovarian cancer and serum from the control group of patients.
Conclusions
Expression of serum anti-tNASP antibody is not a specific screening marker for prostate, pancreatic, or ovarian cancer. Combined use of PSA with anti-tNASP antibody analysis reveals significant elimination of false positive and false negative PSA test results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Campbell University, USA.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
166P - Metabolomic prediction of breast cancer treatment toxicities
Presenter: Max Piffoux
Session: Poster session 01
167P - A tumor immune microenvironment-based model for prediction of everolimus efficacy in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Preliminary results from MIRACLE trial
Presenter: Tan Yujing
Session: Poster session 01
168P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: SHRUTI KAHOL
Session: Poster session 01
169P - Integration of metabolomics and transcriptomics to reveal potential biomarkers associated with treatment response of neoadjuvant therapy in HER2+ breast cancer
Presenter: Ningning Zhang
Session: Poster session 01
170P - Clinical significance and functional role of GPR56 (ADGRG1) in breast cancer
Presenter: Haizhu Chen
Session: Poster session 01
172P - T cell-derived circulating DNA and tumour inflammatory microenvironment in EGFR-mutant advanced non-small cell lung cancer: Correlation with the outcome of EGFR TKI treatment
Presenter: Nicha Zungsontiporn
Session: Poster session 01
173P - Expression of programmed death-ligand 1 and EGFR on circulating tumour cells in advanced lung cancer patients
Presenter: Jayant Khandare
Session: Poster session 01
174P - Frequency and prognostic value of circulating tumor cells in cancer of unknown primary
Presenter: Maria Pouyiourou
Session: Poster session 01
175P - Radiomic biomarker of vessel tortuosity for monitoring treatment change: Preliminary findings in prospective evaluation of ECOG-ACRIN EA5163
Presenter: Pushkar Mutha
Session: Poster session 01